The Life Sciences Report Examines the ProMIS of an

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
203
The Life Sciences Report Examines the ProMIS of an Alzheimer's Cure

SAN FRANCISCO, CA --(Marketwired - May 04, 2017) - With the impacts of Alzheimer's disease on patients, doctors and the health care industry expected to burgeon over the next decade, ProMIS Neurosciences Inc. ( TSX : PMN ), has developed a preclinical program that targets the root cause of the disease, and also offers the potential to get in on an investment with a double bottom line, says Elliot Goldstein, CEO of ProMIS, in this interview with The Life Sciences Report.

Included in this article is: ProMIS Neurosciences Inc.

The Life Sciences Report: Dr. Goldstein, your company, ProMIS Neurosciences Inc., recently presented information on its preclinical development program addressing Alzheimer's disease. Please describe that.

Elliot Goldstein: Our most recent news is a poster presentation, which was given April 28 at the American Academy of Neurology annual meeting in Boston. It's an overview of the current status of our program, and focuses first on our unique proprietary technology, thermodynamic algorithms that run on supercomputers. Using this technology, we've been able to identify five distinct sites, called epitopes, on misfolded toxic forms of Amyloid beta, a known root cause of Alzheimer's disease. An epitope is a target on a molecule, usually a protein, that antibodies can attach to and then neutralize.

The poster also focuses on the cause -- the misfolded forms of Amyloid beta. Also called toxic oligomers or prion-like forms, these toxic forms do two things. They're like gang members in the neighborhood. They're directly toxic to neurons. When they're in the vicinity of neurons, they kill them.

Not only are the oligomers toxic, they propagate, like viruses or prions, throughout the brain. This usually begins in the region of the brain called the hippocampus, where short-term memory is stored. That's why the first signs of Alzheimer's disease involve short-term memory loss. They then spread to the frontal lobes, where cognition, judgment and emotion reside.

We can follow the propagation of these misfolded toxic oligomers or prions. On average it's about 17 years before any symptoms emerge, as these toxic forms of Amyloid beta slowly spread (propagate), destroying billions of neurons. And they propagate in a very simple manner. When they misfold, they lose energy, and become toxic, killing neurons. Any monomer, which is a single strand of normal Amyloid beta in the neighborhood, takes on the same misfolded, toxic shape. The toxic form acts like a template. So now you have two bad actors in your neighborhood; two toxic misfolded oligomers. And those two will then create four, and so on. . .

The poster points out that we've used our two proprietary thermodynamic algorithms to identify five unique targets (epitopes) on the misfolded toxic forms of Amyloid beta. The problem is that these forms are relatively unstable, so traditional pharmaceutical techniques cannot be used to identify sites to attack. To our knowledge, the ProMIS thermodynamic algorithms are the only way to identify these specific targets.

Using our algorithms, not only do we identify the amino acid sequence in the region of misfolding, we also identify the shape, or conformation, of the misfolding. That's really important -- not just the sequence of amino acids exposed, but also the shape of the exposed sequence. We take that misfolded sequence, or epitope, synthesize it, and then use it to immunize mice, thereby raising monoclonal antibodies (mAbs) that are specifically and uniquely directed only against the amino acid sequence and shape of that sequence in the misfolded region. The final result is we now have antibodies that are specific and unique to the toxic misfolded forms of Amyloid beta.

We've also tested to make sure our antibodies don't bind to Amyloid beta monomer or plaque. Indeed, results of prior large pharma trials indicate that products targeting monomer suffer from lack of efficacy, and those targeting plaque are associated with significant adverse effects.

Continue reading this article : The ProMIS of an Alzheimer's Cure

About Streetwise Reports - The Life Sciences Report

Investors rely on The Life Sciences Report to share investment ideas for the biotech, pharmaceutical, medical device, and diagnostics industries. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.

DISCLOSURE:

ProMIS Neurosciences is a sponsor of Streetwise Reports. Streetwise Reports does not accept stock in exchange for its services. Click here for important disclaimers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security. ProMIS Neurosciences Inc. had final approval of the content and is wholly responsible for the validity of the statements. Opinions expressed are the opinions of Elliott Goldstein and not of Streetwise Reports or its officers.

Elliott Goldstein: I was not paid by Streetwise Reports to participate in this interview. I had the opportunity to review the interview for accuracy as of the date of the interview and am responsible for the content of the interview. I or my family own shares of the following companies mentioned in this interview: ProMIS Neurosciences Inc.

Please see the end of the article for the complete disclosure: The ProMIS of an Alzheimer's Cure

Contact Information: Carrie Beal Amaro Associate Publisher Email contact

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Vail Resorts Bets on Music to Deepen Epic Pass Demand

Updated Category News Views 119

A bass drop at 11,000 feet is not merely a party trick when you run 42 mountain resorts. Vail Resorts is putting live music, après programming and destination events squarely beside skiing and riding for winter 2026-27, and the business logic is pretty plain: give people another reason to buy early, stay longer and return with friends. For investors watching MTN, this is...

Continue Reading
NYSE Message Record Puts Market Plumbing Into Focus

Updated Category News Views 120

A trillion messages is not a cute little exchange statistic; it is the sort of number that tells you whether the market’s pipes can keep working when everybody starts shouting at once. NYSE says it handled a record 1.166 trillion messages in one day on November 5, roughly 4% above the prior high set amid April 2025 volatility. Better yet, according to the exchange,...

Continue Reading
LGT Middle East Win Highlights Patient Private Banking

Updated Category News Views 166

A trophy in Dubai is not a balance sheet, but it can be a useful calling card when the clientele measures relationships in decades rather than quarters. LGT Middle East was named Best Pure Play Private Bank at the WealthBriefing MENA Awards 2026, at a ceremony held in Dubai on November 18. For a family-owned wealth manager working with Middle Eastern families, that sort...

Continue Reading
Holland America Puts 2028 Alaska Demand on Display

Updated Category News Views 123

Alaska’s interior is where a cruise brochure either earns its keep or gets exposed. Holland America Line is opening bookings for 2028 Alaska Cruisetours nearly two years ahead, tying a coast-and-land product to the reimagined Oosterdam’s Alaska debut. That is not merely another itinerary release. It is a fairly deliberate attempt to sell a bigger, longer and...

Continue Reading
New York's $1.2M Prison Abuse Deal Raises State Stakes

Updated Category News Views 30

One courtroom result can expose a whole warehouse of institutional neglect, and this one lands with a grim thud. New York has agreed to pay $1.2 million to resolve a claim involving sexual assault by a former corrections officer at Bayview Correctional Facility in Manhattan. The settlement came after a two-week Adult Survivors Act bellwether trial concluded on November 17...

Continue Reading
Africa’s Digital Leap Still Has a 64% Usage Problem

Updated Category News Views 100

A continent can be blanketed in signal and still feel digitally stranded. That is the stubborn fact sitting inside the GSMA Digital Africa Index 2026: mobile broadband reaches 92% of Africa’s population, while only 28% use mobile internet on their own devices. The 64% usage gap is not a rounding error or a tidy policy footnote. It is the whole unfinished job. From an...

Continue Reading
SciBase Sets Its 2027 AGM Nominating Committee Early

Updated Category News Views 94

Four names on a committee roster rarely make anyone pound the table, and they should not. Still, SciBase Holding has put an important bit of corporate housekeeping in place for its 2027 Annual General Meeting: the nominating committee that will handle shareholder-facing governance work ahead of the May 20 meeting in Stockholm. For a small listed medical-technology...

Continue Reading
Ajman Forum Puts Trust at the Center of Crisis Media

Updated Category News Views 82

Rumours do not wait politely for a communications team to finish its meeting. That plain reality sat underneath Abdulla bin Mohammed bin Butti Al Hamed's keynote at Ajman Media Forum 2026, and it is a tougher point than the usual talk about reach, engagement, or flashy new technology. In a crisis, an information vacuum gets filled fast, usually by somebody with no...

Continue Reading
RUDSAK Tests Premium Demand From Toronto to New York

Updated Category News Views 145

A coat rack on Bloor Street can tell a harsher story than a glossy expansion announcement. RUDSAK has opened a Toronto flagship at 55 Bloor Street West in the Manulife Centre and is preparing a boutique at American Dream outside New York City. This is a real step up in retail ambition for the Montréal luxury outerwear house, founded in 1994, and it deserves more than the...

Continue Reading
Shenzhen Three-Way Summit Puts Stability to the Test

Updated Category News Views 153

Three nuclear powers sharing a room in Shenzhen is the sort of headline that makes every risk desk sit upright, even when the paperwork remains thin. CGTN reports that Chinese President Xi Jinping, Russian President Vladimir Putin and U.S. President Donald Trump met on November 19, 2026, in an unprecedented trilateral summit and issued a Declaration toward Peace. That is...

Continue Reading

Top 5 Most Recently Viewed Articles

OmniPathology Partners with Gestalt to Enhance Diagnostic Equity

Updated Category News Views 159

OmniPathology Joins Forces with Gestalt for a Digital Revolution In an exciting development for the medical field, OmniPathology has chosen Gestalt as its strategic partner to innovate their digital pathology solutions. This collaboration signifies a step towards modernizing diagnostic workflows, ultimately enhancing the quality of healthcare services. Transforming...

Continue Reading
Kneat Partners with Leading Global Therapeutics Firm

Updated Category News Views 232

Kneat Partners with Leading Global Therapeutics Firm Kneat.com, inc. (TSX: KSI) (OTCQX: KSIOF), known for its expertise in digitizing and automating essential validation and quality processes, has secured a significant three-year Master Services Agreement with a prominent global therapeutics company. This collaboration aims to fully digitize the validation processes of...

Continue Reading
Exploring Dividend Opportunities with Pfizer and Bristol Myers Squibb

Updated Category News Views 84

The Current State of Dividend Stocks The past year has been quite eventful for stock markets, showcasing significant gains across various indices. However, this surge has made it more difficult for investors to find stocks that are reasonably priced. With the S&P 500 index seeing a substantial increase, identifying attractive buying opportunities has become a challenge...

Continue Reading
Magna International's Impressive Quarterly Progress and Future Outlook

Updated Category News Views 403

Overview of Magna International's Second Quarter Results Magna International Inc. reported robust performance for the second quarter of 2025, showcasing resilience in the face of industry challenges. The company achieved $10.6 billion in sales, despite a 3% decline compared to the previous year, attributed mainly to lower light vehicle production in various markets....

Continue Reading
Guardian Capital Unveils Projected Non-Cash Distributions for ETFs

Updated Category News Views 265

Guardian Capital Announces Estimated 2025 Distributions Guardian Capital LP is pleased to share its estimated annual non-cash year-end distributions for the 2025 tax year related to the Guardian Capital ETFs. Please note that these estimates were made as of mid-November, and while they provide valuable insight, the final amounts may change before the tax year-end in late...

Continue Reading